Taiyen Biotech Co., Ltd. (TPE:1737)

Taiyen Biotech Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1,611	1,551	1,445	1,529	1,726	1,506
Short-Term Investments	-	-	4.24	-	1.06	1.93
Trading Asset Securities	334.51	346.32	390.61	353.18	353.54	381.04
Cash & Short-Term Investments	1,945	1,898	1,840	1,882	2,080	1,889
Cash Growth	0.77%	3.16%	-2.27%	-9.52%	10.15%	-4.10%
Accounts Receivable	527.32	498.3	663.23	650.28	757.6	540.86
Other Receivables	13.88	6.23	23.43	32.78	7.19	33.96
Receivables	541.2	504.53	686.66	683.06	764.79	574.82
Inventory	364.7	427.32	394.74	407.37	395.02	315.56
Other Current Assets	105.91	97.95	105.27	121.26	154.52	121.44
Total Current Assets	2,957	2,927	3,026	3,094	3,395	2,900
Property, Plant & Equipment	4,007	4,023	3,905	3,713	3,564	3,431
Long-Term Investments	-	-	33.96	-	-	-
Other Intangible Assets	10.17	11.71	6.41	5.34	8.53	8.02
Long-Term Deferred Tax Assets	63.65	63.65	81.9	72.12	87.22	64.43
Other Long-Term Assets	1,333	1,355	1,266	1,327	1,413	1,393
Total Assets	8,371	8,381	8,320	8,212	8,468	7,798
Accounts Payable	396.06	419.51	384.5	399.06	485.3	273.15
Short-Term Debt	92	98	100	20	287.53	30
Current Portion of Long-Term Debt	8.33	66.95	15.31	8.65	4.29	4.29
Current Portion of Leases	7.33	8.76	7.26	9.27	10.76	15.16
Current Income Taxes Payable	48.76	43.36	66.29	42.17	79.75	47.22
Current Unearned Revenue	116.82	109.76	98.03	102.23	79.02	33.18
Other Current Liabilities	595.33	418.81	429.62	344.67	358.74	291.88
Total Current Liabilities	1,265	1,165	1,101	926.05	1,305	694.88
Long-Term Debt	2.22	5.56	72.5	68.93	53.08	57.37
Long-Term Leases	23.47	25.93	25.09	28.59	36.33	100.53
Long-Term Unearned Revenue	291.19	297.72	307.19	320.05	332.92	345.78
Long-Term Deferred Tax Liabilities	39.44	39.44	34.38	34.23	34.08	33.93
Other Long-Term Liabilities	140.18	142.08	136.68	109.52	83.67	76.49
Total Liabilities	1,799	1,714	1,771	1,550	1,954	1,433
Common Stock	2,000	2,000	2,000	2,000	2,000	2,000
Additional Paid-In Capital	2,491	2,502	2,502	2,502	2,502	2,502
Retained Earnings	2,086	2,165	1,993	2,022	1,862	1,731
Comprehensive Income & Other	-4.9	-2.63	-3.38	-2.99	-2.16	-2.99
Total Common Equity	6,572	6,664	6,491	6,521	6,361	6,229
Minority Interest	-	3.53	57.6	140.69	152.2	134.75
Shareholders' Equity	6,572	6,668	6,549	6,662	6,513	6,364
Total Liabilities & Equity	8,371	8,381	8,320	8,212	8,468	7,798
Total Debt	133.35	205.2	220.17	135.44	391.98	207.35
Net Cash (Debt)	1,812	1,692	1,619	1,747	1,688	1,681
Net Cash Growth	7.64%	4.51%	-7.29%	3.46%	0.42%	-3.60%
Net Cash Per Share	9.03	8.44	8.08	8.71	8.42	8.38
Filing Date Shares Outstanding	200	200	200	200	200	200
Total Common Shares Outstanding	200	200	200	200	200	200
Working Capital	1,692	1,762	1,925	2,168	2,089	2,206
Book Value Per Share	32.86	33.32	32.46	32.61	31.81	31.15
Tangible Book Value	6,562	6,652	6,485	6,516	6,353	6,221
Tangible Book Value Per Share	32.81	33.26	32.42	32.58	31.76	31.11
Land	1,816	1,816	1,816	1,816	1,736	1,684
Buildings	1,587	1,568	1,423	1,354	1,322	1,300
Machinery	3,514	3,507	3,004	2,837	2,844	2,880
Construction In Progress	123.19	186.56	632.49	440.46	323.04	182.56

Source: S&P Global Market Intelligence. Standard template. Financial Sources.